Swiss National Bank
SMMT icon

Swiss National Bank’s Summit Therapeutics SMMT Stock Holding History

Swiss National Bank’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-275,000
Closed -$1.14M – 2510
2024
Q1 		$1.14M Hold
275,000
– – ﹤0.01% 2152
2023
Q4 		$718K Sell
275,000
-28,800
-9% -$59.2K ﹤0.01% 2398
2023
Q3 		$568K Hold
303,800
– – ﹤0.01% 2478
2023
Q2 		$763K Buy
+303,800
New +$554K ﹤0.01% 2435

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Swiss National Bank's SMMT Position: Q2 2024 in Review

Swiss National Bank sold out of Summit Therapeutics (SMMT) in Q2 2024, closing a stake of 275,000 shares — an estimated $1.14M sold.

Swiss National Bank first reported a position in SMMT in Q2 2023 and held it in 4 quarters. The position peaked at $1.14M in Q1 2024. 123 funds tracked by Wall St. Rank hold SMMT as of Q2 2024.

  • Swiss National Bank reported no remaining Summit Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Swiss National Bank sold 275,000 Summit Therapeutics shares in Q2 2024, an estimated $1.14M.
  • Swiss National Bank first reported a position in Summit Therapeutics in Q2 2023 and held it in 4 quarters.
  • Swiss National Bank's Summit Therapeutics position peaked at $1.14M in Q1 2024.
  • 123 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2024.

Based on Swiss National Bank's 13F filing for Q2 2024, filed 8 Aug 2024.